Novel Serial Positive Enrichment Technology Enables Clinical Multiparameter Cell Sorting

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 May 1

PMID 22545138

Citations 35

Authors

Christian Stemberger

Stefan Dreher

Claudia Tschulik

Christine Piossek

Jeannette Bet

Tori N Yamamoto

Matthias Schiemann

Michael Neuenhahn

Klaus Martin

Martin Schlapschy

Arne Skerra

Thomas Schmidt

Matthias Edinger

Stanley R Riddell

Lothar Germeroth

Dirk H Busch

Affiliations

Soon will be listed here.

Abstract

A general obstacle for clinical cell preparations is limited purity, which causes variability in the quality and potency of cell products and might be responsible for negative side effects due to unwanted contaminants. Highly pure populations can be obtained best using positive selection techniques. However, in many cases target cell populations need to be segregated from other cells by combinations of multiple markers, which is still difficult to achieve--especially for clinical cell products. Therefore, we have generated low-affinity antibody-derived Fab-fragments, which stain like parental antibodies when multimerized via Strep-tag and Strep-Tactin, but can subsequently be removed entirely from the target cell population. Such reagents can be generated for virtually any antigen and can be used for sequential positive enrichment steps via paramagnetic beads. First protocols for multiparameter enrichment of two clinically relevant cell populations, CD4(high)/CD25(high)/CD45RA(high) 'regulatory T cells' and CD8(high)/CD62L(high)/CD45RA(neg) 'central memory T cells', have been established to determine quality and efficacy parameters of this novel technology, which should have broad applicability for clinical cell sorting as well as basic research.

Citing Articles

Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy.

Colina A, Shah V, Shah R, Kozlik T, Dash R, Terhune S Front Mol Med. 2024; 4:1310002.

PMID: 39086435 PMC: 11285593. DOI: 10.3389/fmmed.2024.1310002.

Fully closed cell sorter for immune cell therapy manufacturing.

Matsumoto M, Tashiro S, Ito T, Takahashi K, Hashimoto G, Kajihara J Mol Ther Methods Clin Dev. 2023; 30:367-376.

PMID: 37637381 PMC: 10457513. DOI: 10.1016/j.omtm.2023.07.012.

Aptamer-Based Chromatographic Methods for Efficient and Economical Separation of Leukocyte Populations.

Ling M, Cardle I, Song K, Yan A, Kacherovsky N, Jensen M ACS Biomater Sci Eng. 2023; 9(8):5062-5071.

PMID: 37467493 PMC: 11016351. DOI: 10.1021/acsbiomaterials.3c00651.

Next generation automated traceless cell chromatography platform for GMP-compliant cell isolation and activation.

Radisch S, Poltorak M, Wagner M, Cletiu V, Radisch C, Treise I Sci Rep. 2022; 12(1):6572.

PMID: 35449227 PMC: 9023455. DOI: 10.1038/s41598-022-10320-x.

Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition).

Cossarizza A, Chang H, Radbruch A, Abrignani S, Addo R, Akdis M Eur J Immunol. 2021; 51(12):2708-3145.

PMID: 34910301 PMC: 11115438. DOI: 10.1002/eji.202170126.

References

Fiedler M, Skerra A . Use of thiophilic adsorption chromatography for the one-step purification of a bacterially produced antibody F(ab) fragment without the need for an affinity tag. Protein Expr Purif. 1999; 17(3):421-7. DOI: 10.1006/prep.1999.1142. View

Hoffmann P, Eder R, Boeld T, Doser K, Piseshka B, Andreesen R . Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood. 2006; 108(13):4260-7. DOI: 10.1182/blood-2006-06-027409. View

Altman J, Moss P, Goulder P, Barouch D, McHeyzer-Williams M, Bell J . Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996; 274(5284):94-6. DOI: 10.1126/science.274.5284.94. View

Kohm A, McMahon J, Podojil J, Begolka W, DeGutes M, Kasprowicz D . Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol. 2006; 176(6):3301-5. DOI: 10.4049/jimmunol.176.6.3301. View

Riley J, June C, Blazar B . Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity. 2009; 30(5):656-65. PMC: 2742482. DOI: 10.1016/j.immuni.2009.04.006. View

Schmidt T, Skerra A . The Strep-tag system for one-step purification and high-affinity detection or capturing of proteins. Nat Protoc. 2007; 2(6):1528-35. DOI: 10.1038/nprot.2007.209. View

Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H . Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005; 202(3):379-86. PMC: 2213070. DOI: 10.1084/jem.20040613. View

Chatenoud L . CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol. 2003; 3(2):123-32. DOI: 10.1038/nri1000. View

Yang S, Gattinoni L, Luca G, Liu F, Ji Y, Yu Z . In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol Immunother. 2011; 60(5):739-49. PMC: 3080434. DOI: 10.1007/s00262-011-0977-7. View

10.

Bes C, Briant-Longuet L, Cerutti M, Heitz F, Troadec S, Pugniere M . Mapping the paratope of anti-CD4 recombinant Fab 13B8.2 by combining parallel peptide synthesis and site-directed mutagenesis. J Biol Chem. 2003; 278(16):14265-73. DOI: 10.1074/jbc.M210694200. View

11.

Randolph D, Fathman C . Cd4+Cd25+ regulatory T cells and their therapeutic potential. Annu Rev Med. 2006; 57:381-402. DOI: 10.1146/annurev.med.57.121304.131337. View

12.

Kjer-Nielsen L, Dunstone M, Kostenko L, Ely L, Beddoe T, Mifsud N . Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3. Proc Natl Acad Sci U S A. 2004; 101(20):7675-80. PMC: 419665. DOI: 10.1073/pnas.0402295101. View

13.

Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A . Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009; 30(6):899-911. DOI: 10.1016/j.immuni.2009.03.019. View

14.

Edinger M, Hoffmann P, Ermann J, Drago K, Fathman C, Strober S . CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003; 9(9):1144-50. DOI: 10.1038/nm915. View

15.

Schlapschy M, Gruber H, Gresch O, Schafer C, Renner C, Pfreundschuh M . Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach. Protein Eng Des Sel. 2005; 17(12):847-60. DOI: 10.1093/protein/gzh098. View

16.

Skerra A . A general vector, pASK84, for cloning, bacterial production, and single-step purification of antibody Fab fragments. Gene. 1994; 141(1):79-84. DOI: 10.1016/0378-1119(94)90131-7. View

17.

Schmitt A, Tonn T, Busch D, Grigoleit G, Einsele H, Odendahl M . Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion. 2010; 51(3):591-9. DOI: 10.1111/j.1537-2995.2010.02940.x. View

18.

Turtle C, Riddell S . Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Curr Opin Immunol. 2011; 23(2):299-305. PMC: 3130496. DOI: 10.1016/j.coi.2010.12.012. View

19.

Rosenberg S, Restifo N, Yang J, Morgan R, Dudley M . Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8(4):299-308. PMC: 2553205. DOI: 10.1038/nrc2355. View

20.

Berger C, Jensen M, Lansdorp P, Gough M, Elliott C, Riddell S . Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2007; 118(1):294-305. PMC: 2104476. DOI: 10.1172/JCI32103. View